# The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer

> **NCT05461261** · PHASE2 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 50 (estimated)

## Conditions studied

- Hormone Sensitive Metastatic Prostate Cancer
- DNA Damage Repair Deficiency
- Chemotherapy Effect
- Chemotherapeutic Toxicity

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Prednisolone Acetate
- **DRUG:** Platinum-based drugs

## Key facts

- **NCT ID:** NCT05461261
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05461261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05461261, "The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05461261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*